Kindly Md, Inc. rose 2.10% in after-hours trading, with the company announcing a strategic restructuring that includes a 50% reduction in workforce, anticipated to result in annualized cost savings of approximately $13M. The restructuring is designed to sharpen operational focus and align resources with the Company’s long-term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia.
Comments
No comments yet